Intensive Virtual Treatment With Remote Abstinence Monitoring for Alcohol Use Disorder
NCT ID: NCT05722483
Last Updated: 2024-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
63 participants
INTERVENTIONAL
2023-01-30
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ambulatory Alcohol Detoxification With Remote Monitoring
NCT03582150
Deep Brain Stimulation (DBS) for the Treatment of Refractory Alcohol Use Disorder (AUD): Pilot Trial
NCT03660124
Brief Internet Intervention for Hazardous Alcohol Use to People Seeking Online Help for Depression
NCT03421080
Remote Treatment of Alcohol Withdrawal
NCT04858490
The Efficacy of Robot-Assisted Intelligent Rehabilitation Treatment in Patients With AUD
NCT05675553
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Virtual Intensive Outpatient Program
Participants will be treated in a 4 week program involving daily psychotherapy groups, weekly individual therapy and medication management, as well as daily breathalyzer monitoring.
Virtual Intensive Outpatient Program
Components of the intervention include a cognitive behavioral therapy for alcohol use disorder group (12 sessions), a DBT skills group (12 sessions), a Health and Wellness group (8 sessions), weekly individual therapy, weekly medication management appointments, and abstinence monitoring multiple times per day using breathalyzers equipped with facial recognition and internet connectivity.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Virtual Intensive Outpatient Program
Components of the intervention include a cognitive behavioral therapy for alcohol use disorder group (12 sessions), a DBT skills group (12 sessions), a Health and Wellness group (8 sessions), weekly individual therapy, weekly medication management appointments, and abstinence monitoring multiple times per day using breathalyzers equipped with facial recognition and internet connectivity.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able to communicate and provide informed consent in English
3. Diagnosis of moderate to severe AUD, based on the Structured Clinical Interview for DSM-5, Research Version (SCID-5-RV)
4. Risky alcohol consumption, defined as \> 10 drinks per week for females and \> 15 drinks for males on average during the 60 days prior to the eligibility assessment.
5. Motivated to abstain from alcohol for the month-long treatment period (longer-term harm reduction goals are permitted)
6. Access to a private location from which to participate in the program for the duration of the study.
7. Able and motivated to complete all aspects of the program, including attending all virtual intensive outpatient program sessions (this includes being available for group and individual sessions throughout the day on weekdays) and completing multiple daily breathalyzer readings throughout the entire program. Individuals planning to be out of the province during the virtual intensive outpatient program will not be permitted to enroll.
8. Enrolled in the Ontario Health Insurance Plan (OHIP)
Exclusion Criteria
2. Active and severe suicidal ideation at time of eligibility assessment or suicide attempt within the past month.
3. Diagnosis of opioid use disorder or sedative use disorder within the past year based on the SCID-5 (other concurrent substance use disorders such as cannabis use disorder will not be exclusionary)
4. History of alcohol withdrawal delirium
5. Currently pregnant, breastfeeding, or intending to become pregnant or breastfeed during the study.
6. Enrollment in another study that conflicts with the procedures or scientific integrity of this study
7. Individuals planning to be out of the province during the virtual intensive outpatient program will not be permitted to enroll.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Centre for Addiction and Mental Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew Sloan, MD
Role: PRINCIPAL_INVESTIGATOR
Centre for Addiction and Mental Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Addiction and Mental Health
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kelly Xiao, BSc
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
055/2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.